Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | RPA1 | P27694 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765280 | 0.90 | CHRNA7 (0.50) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL1764971 | 0.90 | TP53 (0.48) | CHRNA7CA9FAAHMGLLTP53 | |
| SCHEMBL1764882 | 0.90 | CHRNA7 (0.50) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL1526084 | 0.89 | CHRNA7 (0.54) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL1764884 | 0.88 | CHRNA7 (0.53) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL1765031 | 0.86 | CHRNA7 (0.60) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL1765446 | 0.86 | CHRNA7 (0.49) | CHRNA7CA9FAAHMGLLTP53 | |
| SCHEMBL1765484 | 0.86 | CHRNA7 (0.52) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL1764980 | 0.86 | CHRNA7 (0.53) | CHRNA7RPA1CA9FAAHMGLL | |
| SCHEMBL3434352 | 0.86 | RPA1 (0.39) | CHRNA7RPA1RXFP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | CHRNA7 3365/4885RPA1 3978/4885CA9 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.